BioAge Labs’ (BIOA) Buy Rating Reiterated at Roth Capital

BioAge Labs (NASDAQ:BIOA)‘s stock had its “buy” rating restated by analysts at Roth Capital in a research note issued on Wednesday, Benzinga reports. They currently have a $25.00 price objective on the stock. Roth Capital’s target price would indicate a potential upside of 175.48% from the company’s current price.

BIOA has been the topic of several other research reports. Needham & Company LLC lowered their price objective on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. BTIG Research reissued a “buy” rating and set a $40.00 target price on shares of BioAge Labs in a research report on Tuesday. Wall Street Zen lowered shares of BioAge Labs from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Jefferies Financial Group set a $21.00 price target on shares of BioAge Labs in a research report on Friday, July 31st. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $36.57.

BioAge Labs Trading Down 3.5%

BioAge Labs stock traded down $0.33 during midday trading on Wednesday, reaching $9.07. The stock had a trading volume of 226,552 shares, compared to its average volume of 692,858. The company has a fifty day moving average price of $15.89 and a two-hundred day moving average price of $17.67. BioAge Labs has a 12 month low of $4.68 and a 12 month high of $25.95. The company has a market capitalization of $416.54 million, a P/E ratio of -3.82 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%.The company had revenue of $2.45 million for the quarter. On average, equities research analysts predict that BioAge Labs will post -2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in BioAge Labs during the second quarter worth about $69,831,000. Jupiter Topco LLC bought a new position in shares of BioAge Labs during the 2nd quarter worth approximately $52,597,000. Janus Henderson Group PLC lifted its position in shares of BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after buying an additional 1,685,063 shares in the last quarter. Octagon Capital Advisors LP boosted its stake in shares of BioAge Labs by 9.4% in the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock worth $30,573,000 after buying an additional 150,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of BioAge Labs by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after buying an additional 93,694 shares during the last quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.